trial
as of 2026-07-01A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
NCTId NCT05953740
at a glance
Phase 1 · Completed
Enrollment 17 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2024-02-15
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
17 (actual)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Triple
Start
2023-09-15
Primary completion
2024-02-15
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Indications
Sponsors
Merck Sharp & Dohme LLCLead Sponsor
Sites
4 total
Glendale, United StatesHallandale, United StatesHollywood, United StatesMarlton, United States
Facts & assertions
4 sourced
Enrollment
17
Phase
PHASE1
Primary Completion Date
2024-02-15
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
company
indication
indication
indication